Роль тиреотропного гормону у генезі раку щитоподібної залози

О. В. Черненко, В. Г. Хоперія

Повний текст:



Aoki Y., Belin R.M., Clickner R., Jeffries R., Phillips L., Mahaffey K.R. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002) // Thyroid. – 2007. – Vol. 17. – P. 1211-1223.

Baker J.R. The immune response to papillary thyroid cancer // Journal of Clinical Endocrinology and Metabolism. – 1995. – Vol. 80. – P. 3419-3420.

Balme H.W. Metastatic carcinoma of the thyroid successfully treated with thyroxine // Lancet. – 1954. – Vol. 266. – P. 812-813.

Belfiore A., La Rosa G.L., La Porta G.A., Giuffrida D., Milazzo G., Lupo L., Regalbuto C., Vigneri R. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity // American Journal of Medicine. – 1992. – Vol. 93. – P. 363-369.

Biondi B., Filetti S., Schlumberger M. Thyroidhormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice // Endocrinology and Metabolism. – 2005. – Vol. 1. – P. 32-40.

Boelaert K., Horacek J., HolderR.L., Watkinson J.C., Sheppard M.C., Franklyn J.A. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fineneedle aspiration // Journal of Clinical Endocrinology and Metabolism. – 2006. – Vol. 91. – P. 4295-4301.

Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? // Journal of Clinical Endocrinology and Metabolism. – 2008. – Vol. 93. – P. 1167-1169.

Brewer C., Yeager N., Di C.A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT // Cancer Research. – 2007. – Vol. 67. – P. 8002-8006.

British Thyroid Association and Royal College of Physicians // Guidelines for the management of thyroid cancer. – 2007. – edn 2. [].

Carayon P., Thomas-Morvan C., Castanas E., Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity // Journal of Clinical Endocrinology and Metabolism. – 1980. – Vol. 51. – P. 915-920.

Chang T.C., Kuo S.H., Liaw K.Y., Chang C.C., Chen F.W. Cell kinetics, DNA content and TSH receptor-adenylate cyclase system in differentiated thyroid cancer // Clinical Endocrinology. – 1988. – Vol. 29. – P. 477-484.

Cipolla C., Sandonato L., Graceffa G., Fricano S., Torcivia A., Vieni S., Latteri S., Latteri M.A. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma // American Surgeon. – 2005. – Vol. 71. – P. 874-878.

Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., McIver B., Sherman S.I., Tuttle R.M. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. – 2006. – Vol. 16. – P. 1-33.

Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002 // Journal of the American Medical Association. – 2006. – Vol. 295. – P. 2164-2167.

Dean D.S., Hay I.D. Prognostic indicators in differentiated thyroid carcinoma // Cancer Control. – 2000. – Vol. 7. – P. 229-239.

Derwahl M., Broecker M., Kraiem Z. Clinical review 101: thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors // Journal of Clinical Endocrinology and Metabolism. – 1999. – Vol. 84. – P. 829-834.

Feldt-Rasmussen U. Iodine and cancer // Thyroid. – 2001. – Vol. 11. – P. 483-486.

Fenzi G.F., Ceccarelli C., Macchia E., Monzani F., Bartalena L., Giani C., Ceccarelli P., Lippi F., Baschieri L., Pinchera A. Reciprocal changes of serum thyroglobulin and TSH in residents of a moderate endemic goitre area // Clinical Endocrinology. – 1985. – Vol. 23. – P. 115-122.

Filetti S., Belfiore A., Amir S.M., Daniels G.H., Ippolito O., VigneriR., Ingbar S.H. The role of thyroid- stimulating antibodies of Graves' disease in differentiated thyroid cancer // New England Journal of Medicine. – 1988. – Vol. 318. – P. 753-759.

Fiore E., Rago T., Provenzale M.A., Scutari M., Ugolini C., Basolo F., Di Coscio G., Berti P., Grasso L., Elisei R., Pinchera A., Vitti P. Lower levels of TSH are associated to a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role // Endocrine-Related Cancer. – 2009 – Vol. 16. – P. 1251-1260.

Franceschi S. Iodine intake and thyroid carcinoma – a potential risk factor // Experimental and Clinical Endocrinology and Diabetes. – 1998. – Vol. 106. – P. 38-44.

Gharib H. Changing trends in thyroid practice: understanding nodular thyroid disease // Endocrine Practice. – 2004. – Vol. 10. – P. 31-39.

Goldberg R.C., Lindsay S., Nichols C.W.Jr., Chaikoff I.L. Induction of neoplasms in thyroid glands of rats by subtotal thyroidectomy and by the injection of one microcurie of I-131 // Cancer Research. – 1964. – Vol. 24. – P. 35-43.

Gudmundsson J., Sulem P., Gudbjartsson D.F., Jonasson J.G., Sigurdsson A., Bergthorsson J.T., He H., Blondal T., Geller F., Jakobsdottir M. et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations // Nature Genetics. – 2009. – Vol. 41. – P. 460-464.

Hales I.B., McElduff A., Crummer P., Clifton-Bligh P., Delbridge L., Hoschl R., Poole A., Reeve T.S., Wilmshurst E., Wiseman J. Does Graves' disease or thyrotoxicosis affect the prognosis of thyroid cancer // Journal of Clinical Endocrinology and Metabolism. – 1992. – Vol. 75. – P. 886-889.

Haymart M.R. Understanding the relationship between age and thyroid cancer // Oncologist. – 2009. – Vol. 14. – P. 216-221.

Haymart M.R., Repplinger D.J., Leverson G.E., Elson D.F., Sippel R.S., Jaume J.C., Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage // Journal of Clinical Endocrinology and Metabolism. – 2008. – Vol. 93. – P. 809-814.

Haymart M.R., Glinberg S.L., Liu J., Sippel R.S., Jaume J.C., Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension // Clinical Endocrinology. – 2009. – Vol. 71. – P. 434-439.

Hegedus L. Clinical practice. The thyroid nodule / / New England Journal of Medicine. – 2004. – Vol. 351. – P. 1764-1771.

Hegedus L., Bonnema S.J., Bennedbaek F.N. Management of simple nodular goiter: current status and future perspectives // Endocrine Reviews. – 2003. – Vol. 24. – P. 102-132.

Hollowell J.G., Staehling N.W., Flanders W.D., Hannon W.H., Gunter E.W., Spencer C.A., Braverman L.E. Serum TSH T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) // Journal of Clinical Endocrinology and Metabolism. – 2002. – Vol. 87. – P. 489-499.

Holm L.E., Blomgren H., Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis // New England Journal of Medicine. – 1985. – Vol. 312. – P. 601-604.

Hovens G.C., Stokkel M.P., Kievit J., Corssmit E.P., Pereira A.M., Romijn J.A., Smit J.W. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer // Journal of Clinical Endocrinology and Metabolism. – 2007. – Vol. 92. – P. 2610-2615.

Ichikawa Y., Saito E., Abe Y., Homma M., Muraki T. Presence of TSH receptor in thyroid neoplasms / / Journal of Clinical Endocrinology and Metabolism. – 1976. – Vol. 42. – P. 395-398.

Jonklaas J., Sarlis N.J., Litofsky D., Ain K.B., Bigos S.T., Brierley J.D., Cooper D.S., Haugen B.R., Ladenson P.W., Magner J. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy // Thyroid. – 2006. – Vol. 16. – P. 1229-1242.

Jonklaas J., Nsouli-Maktabi H., Soldin S.J. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer // Thyroid. – 2008. – Vol. 18. – P. 943-952.

Kimura T., Van Keymeulen A., Golstein J., Fusco A., Dumont J.E., Roger P.P. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models // Endocrine Reviews. – 2001. – Vol. 22. – P. 631-656.

Kurukahvecioglu O., Taneri F., Yuksel O., Aydin A., Tezel E., Onuk E. Total thyroidectomy for the treatment of Hashimoto's thyroiditis coexisting with papillary thyroid carcinoma // Advances in Therapy. – 2007. – Vol. 24. – P. 510-516.

Lind P., Langsteger W., Molnar M., Gallowitsch H.J., Mikosch P., Gomez I. Epidemiology of thyroid diseases in iodine sufficiency // Thyroid. – 1998. – Vol. 8. – P. 1179-1183.

Mann K. Evaluation of risk in autonomously functioning thyroid nodules // Experimental and Clinical Endocrinology & Diabetes. – 1998. – Vol. 106. – P. 23-26.

Marqusee E., Benson C.B., Frates M.C., Doubilet P.M., Larsen P.R., Cibas E.S., Mandel S.J. Usefulness of ultrasonography in the management of nodular thyroid disease // Annals of Internal Medicine. – 2000. – Vol. 133. – P. 696-700.

Matsuo K., Friedman E., Gejman P.V., Fagin J.A. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms // Journal of Clinical Endocrinology and Metabolism. – 1993. – Vol. 76. – P. 1446-1451.

Mazzaferri E.L. An overview of the management of papillary and follicular thyroid carcinoma // Thyroid. – 1999. – Vol. 9. – P. 421-427.

Mazzaferri E.L. Thyroid cancer and Graves' disease: the controversy ten years later // Endocrine Practice. – 2000. – Vol. 6. – P. 221-225.

Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer // American Journal of Medicine. – 1994. – Vol. 97. – P. 418-428.

Nagataki S., Nystrom E. Epidemiology and primary prevention of thyroid cancer // Thyroid. – 2002. – Vol. 12. – P. 889-896.

Okayasu I., Fujiwara M., Hara Y., Tanaka Y., Rose N.R. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans // Cancer. – 1995. – Vol. 76. – P. 2312-2318.;2-h

Papini E., Petrucci L., Guglielmi R., Panunzi C., Rinaldi R., Bacci V., Crescenzi A., Nardi F., Fabbrini R., Pacella C.M. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules // Journal of Clinical Endocrinology and Metabolism. – 1998. – Vol. 83. – P. 780-783.

Pellegriti G., Belfiore A., Giuffrida D., Lupo L., Vigneri R. Outcome of differentiated thyroid cancer in Graves' patients // Journal of Clinical Endocrinology and Metabolism. – 1998. – Vol. 83. – P. 2805-2809.

Polyzos S.A., Kita M., Efstathiadou Z., Poulakos P., Slavakis A., Sofianou D., Flaris N., Leontsini M., Kourtis A., Avramidis A. Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules // Journal of Cancer Research and Clinical Oncology. – 2008. – Vol. 134. – P. 953-960.

Pujol P., Daures J.P., Nsakala N., Baldet L., Bringer J., Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer // Journal of Clinical Endocrinology and Metabolism. – 1996. – Vol. 81. – P. 4318-4323.

Reiners C., Wegscheider K., Schicha H., Theissen P., Vaupel R., Wrbitzky R., Schumm-Draeger P.M. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees // Thyroid. – 2004. – Vol. 14. – P. 926-932.

Ron E., Lubin J.H., Shore R.E., Mabuchi K., Modan B., Pottern L.M., Schneider A.B., Tucker M.A., Boice J.D. Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies // Radiation Research. – 1995. – Vol. 141. – P. 259-277.

Ross D.S. Predicting thyroid malignancy // Journal of Clinical Endocrinology and Metabolism. – 2006. – Vol. 91. – P. 4253-4255.

Sanders L.E., Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment // Archives of Surgery. – 1998. – Vol. 133. – P. 419-425.

Satta M.A., De R.G., Testa A., Maussier M.L., Valenza V., Rabitti C., Saletnich I., D'Ugo D., Picciocchi A. Thyroid cancer in suppressed contralateral lobe of patients with hot thyroid nodule // European Journal of Cancer. – 1993. – Vol. 29A. – P. 1190-1192.

Shi Y., Zou M., Farid N.R. Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis // Clinical Endocrinology. – 1993. – Vol. 39. – P. 269-274.

Simpson W.J., Panzarella T., Carruthers J.S., Gospodarowicz M.K., Sutcliffe S.B. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients // International Journal of Radiation Oncology, Biology, Physics. – 1988. – Vol. 14. – P. 1063-1075.

Singh B., Shaha A.R., Trivedi H., Carew J.F., Poluri A., Shah J.P. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome // Surgery. – 1999. – Vol. 126. – P. 1070-1076.

Surks M.I., Hollowell J.G. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism // Journal of Clinical Endocrinology and Metabolism. – 2007. – Vol. 92. – P. 4575-4582.

Tunbridge W.M., Evered D.C., Hall R., Appleton D., Brewis M., Clark F., Evans J.G., Young E., Bird T., Smith P.A. The spectrum of thyroid disease in a community: the Whickham survey // Clinical Endocrinology. – 1977. – Vol. 7. – P. 481-493.

Vander J.B., Gaston E.A., Dawber T.R. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy // Annals of Internal Medicine. – 1968. – Vol. 69. – P. 537-540.

Vermiglio F., Lo P., Violi M.A., Moleti M., Castagna M.G., Finocchiaro M.D., Mattina F., Mandolfino M., Zimbaro G., Trimarchi F. Changes in both size and cytological features of thyroid nodule after levothyroxine treatment // Clinical Endocrinology. – 2003. – Vol. 59. – P. 347-353.

Du Villard J.A., Wicker R., Crespo P., Russo D., Filetti S., Gutkind J.S., Sarasin A., Suarez H.G. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation // Oncogene. – 2000. – Vol. 19. – P. 4896-4905.

Walker R.P., Paloyan E. The relationship between Hashimoto's thyroiditis, thyroid neoplasia, and primary hyperparathyroidism // Otolaryngologic Clinics of North America. – 1990. – Vol. 23. – P. 291-302.

Yano Y., Shibuya H., Kitagawa W., Nagahama M., Sugino K., Ito K., Ito K. Recent outcome of Graves' disease patients with papillary thyroid cancer // European Journal of Endocrinology. – 2007. – Vol. 157. – P. 325-329.

Yeager N., Klein-Szanto A., Kimura S., Di C.A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis // Cancer Research. – 2007. – Vol. 67. – P. 959-966.

Zelmanovitz F., Genro S., Gross J.L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses // Journal of Clinical Endocrinology and Metabolism. – 1998. – Vol. 83. – P. 3881-3885.

Пристатейна бібліографія ГОСТ

Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter